Literature DB >> 24450546

Editors' pick 2013.

Albert Ferro1, Yoon K Loke, Lionel D Lewis, Andrew Somogyi, Adam F Cohen, James M Ritter.   

Abstract

Mesh：

Year:  2014        PMID： 24450546      PMCID： PMC4014024          DOI： 10.1111/bcp.12303

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  16 in total

1.  R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Authors:  Sylvia Braselmann; Vanessa Taylor; Haoran Zhao; Su Wang; Catherine Sylvain; Muhammad Baluom; Kunbin Qu; Ellen Herlaar; Angela Lau; Chi Young; Brian R Wong; Scott Lovell; Thomas Sun; Gary Park; Ankush Argade; Stipo Jurcevic; Polly Pine; Rajinder Singh; Elliott B Grossbard; Donald G Payan; Esteban S Masuda
Journal:  J Pharmacol Exp Ther       Date:  2006-08-31       Impact factor: 4.030

2.  A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics.

Authors:  Peter Hodsman; Claire Ashman; Anthony Cahn; Erika De Boever; Nicholas Locantore; Adrian Serone; Isabelle Pouliquen
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 3.  Gene doping: gene delivery for olympic victory.

Authors:  David Gould
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

4.  Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.

Authors:  Xiaojing Xu; Lifang Han; Li Duan; Yingchun Zhao; Huaping Yang; Boting Zhou; Rui Ma; Ruixia Yuan; Honghao Zhou; Zhaoqian Liu
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration.

Authors:  Shuken Kai; Eiji Kondo; Yasuyuki Kawaguchi; Nobuto Kitamura; Kazunori Yasuda
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

6.  Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway.

Authors:  Satnam Lidder; Andrew J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

7.  Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects.

Authors:  Zahid Ali; Bart Laurijssens; Thor Ostenfeld; Simon McHugh; Anastasia Stylianou; Paul Scott-Stevens; Louise Hosking; Odile Dewit; Jill C Richardson; Chao Chen
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

8.  Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.

Authors:  Muhammad Baluom; Elliott B Grossbard; Tim Mant; David T W Lau
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

9.  Validation of suicide and self-harm records in the Clinical Practice Research Datalink.

Authors:  Kyla H Thomas; Neil Davies; Chris Metcalfe; Frank Windmeijer; Richard M Martin; David Gunnell
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

10.  Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

Authors:  David Eastwood; Chris Bird; Paula Dilger; Jason Hockley; Lucy Findlay; Stephen Poole; Susan J Thorpe; Meenu Wadhwa; Robin Thorpe; Richard Stebbings
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.